Clinical Trials Logo

Advanced-stage Ovarian Cancer clinical trials

View clinical trials related to Advanced-stage Ovarian Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03491033 Completed - Clinical trials for Advanced-stage Ovarian Cancer

Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy

Start date: August 28, 2017
Phase:
Study type: Observational

Tumor response to NAC predicts survival and can be considered a surrogate prognostic marker. Three tiered chemotherapy response score (CRS) of omental tissue sections showed a significant association with survival. In patients with CRS 1 or 2, NAC selects a subpopulation of chemotherapy resistant tumor cells. This study will examine comprehensive molecular analyses on the residual disease of 104 clinically defined high-grade serous carcinoma after NAC, including next-generation sequencing on 14 matched pretreatment biopsies. This information together with immune marker expression and BRCA expression, will provide a unique opportunity to guide biomarker-driven adjuvant studies targeting these chemotherapy-resistant tumor cells.